ABBV Sep 2024 105.000 call
| Previous Close | 53.78 |
| Open | N/A |
| Bid | 61.70 |
| Ask | 65.60 |
| Strike | 105.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 53.78 - 53.78 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
Barrons.comTeva Stock Is Powering Ahead as Schizophrenia News Offsets Mixed Earnings
The key question for investors is how the company’s pipeline of new medicines might perform in coming years.
CNW GroupQULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine.
Insider Monkey15 Best S&P 500 Dividend Stocks To Buy Now
In this article, we discuss 15 best S&P 500 dividend stocks to buy now. You can skip our detailed analysis of dividend stocks in the S&P 500 and their past performance, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy Now. It’s been a dynamic first quarter for the stock market. […]
